{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:13:45Z","timestamp":1791292425699,"version":"4.1.0"},"reference-count":21,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016956","name":"Melinta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Invasive candidiasis (IC) is increasing due to the rising numbers of immunocompromised patients. Increasing azole resistance rates and daily dosing required for most echinocandins have complicated its treatment. The approval of rezafungin has provided an option for weekly echinocandin treatment. The susceptibility of less common <jats:italic>Candida<\/jats:italic> spp. to rezafungin is unclear. We looked at the minimum inhibitory concentrations (MICs) of rezafungin and comparator agents against <jats:italic>Candida<\/jats:italic> spp. collected as part of a global surveillance program.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>The CLSI reference broth microdilution method was performed to test 590 clinical isolates of 28 different <jats:italic>Candida<\/jats:italic> species, including <jats:italic>Candida auris<\/jats:italic>. Species\u2010specific interpretative criteria by breakpoints or epidemiological cutoff values were applied where available.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Rezafungin was within \u00b12\u2010fold MIC<jats:sub>50<\/jats:sub>\/<jats:sub>90<\/jats:sub> values of other echinocandins against all <jats:italic>Candida<\/jats:italic> spp. The lowest rezafungin MIC<jats:sub>50<\/jats:sub>\/<jats:sub>90<\/jats:sub> values were noted against <jats:italic>C. kefyr<\/jats:italic> (0.03\/0.06\u2009mg\/L) and <jats:styled-content style=\"fixed-case\"><jats:italic>C. pelliculosa<\/jats:italic><\/jats:styled-content> (0.015\/0.03\u2009mg\/L). Higher rezafungin MIC<jats:sub>50<\/jats:sub>\/<jats:sub>90<\/jats:sub> values were noted for <jats:styled-content style=\"fixed-case\"><jats:italic>C. guilliermondii<\/jats:italic><\/jats:styled-content> (1\/1\u2009mg\/L) and for isolates in the <jats:styled-content style=\"fixed-case\"><jats:italic>C. parapsilosis<\/jats:italic><\/jats:styled-content> complex (<jats:italic>C. orthopsilosis<\/jats:italic>, 0.5\/1\u2009mg\/L, <jats:italic>C. metapsilosis<\/jats:italic>, 0.12\/0.5\u2009mg\/L). Rezafungin was active against 97.7% of <jats:italic>C. dubliniensis<\/jats:italic> and 95.4% of <jats:styled-content style=\"fixed-case\"><jats:italic>C. auris<\/jats:italic><\/jats:styled-content> by CLSI breakpoints. For fluconazole, 69.7% of <jats:styled-content style=\"fixed-case\"><jats:italic>C. guilliermondii<\/jats:italic><\/jats:styled-content>, 85.7% of <jats:italic>C. orthopsilosis<\/jats:italic>, and 100% of <jats:italic>C. metapsilosis<\/jats:italic> were wildtype by ECV, and 10.8% of <jats:styled-content style=\"fixed-case\"><jats:italic>C. auris<\/jats:italic><\/jats:styled-content> were susceptible by CDC breakpoint.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Rezafungin was highly active by in\u00a0vitro testing against less common <jats:italic>Candida<\/jats:italic> spp. Rezafungin MICs were comparable to other echinocandins. Rezafungin is a desirable therapeutic alternative due to its reduced dosing frequency.<\/jats:p><\/jats:sec>","DOI":"10.1111\/myc.70001","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T04:14:46Z","timestamp":1732076086000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The In\u00a0Vitro Activity of Rezafungin Against Uncommon Species of <i>Candida<\/i>"],"prefix":"10.1111","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9785-5034","authenticated-orcid":false,"given":"Marisa L.","family":"Winkler","sequence":"first","affiliation":[{"name":"Element Iowa City (JMI Laboratories)  North Liberty Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rhomberg","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories)  North Liberty Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail L.","family":"Klauer","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories)  North Liberty Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Edeker","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories)  North Liberty Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories)  North Liberty Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ933"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy358"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00570-24"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof5030067"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/598327"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00701-16"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00131-14"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S383785"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.05115-22"},{"key":"e_1_2_10_11_1","unstructured":"CDC \u201cDrug\u2010ResistantCandida auris \u201d2019 https:\/\/www.cdc.gov\/fungal\/Candida\u2010auris\/index.html."},{"key":"e_1_2_10_12_1","unstructured":"WHO \u201cWHO Fungal Priority Pathogens List to Guide Research Development and Public Health Action \u201d2022 https:\/\/www.who.int\/publications\/i\/item\/9789240060241."},{"key":"e_1_2_10_13_1","unstructured":"CDC \u201cAntifungal Susceptibility Testing forC. auris \u201dPrevention CfDCa 2024 https:\/\/www.cdc.gov\/candida\u2010auris\/hcp\/laboratories\/antifungal\u2010susceptibility\u2010testing.html."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myad021"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000111"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120452"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2011.140685"},{"key":"e_1_2_10_18_1","volume-title":"M27 M44S Ed3. Performance Standards for Antifungal Susceptibility Testing of Yeasts","author":"CLSI","year":"2022"},{"key":"e_1_2_10_19_1","unstructured":"M. L.Winkler L.Deshpande J. H.Kimbrough P.Rhomberg A.Klauer andM.Castanheira \u201cUse of Anidulafungin Caspofungin and Micafungin as Surrogate Markers to Predict in Vitro Susceptibility to Rezafungin Among 5720 Candida Species Clinical Isolates Using CLSI Methods and Interpretive Criteria \u201d2024."},{"key":"e_1_2_10_20_1","unstructured":"Anonymous \u201cSENTRY MVP \u201daccessed April 22 2024 https:\/\/sentry\u2010mvp.jmilabs.com\/."},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-012-9551-x"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01132-23"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.70001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T09:07:16Z","timestamp":1732784836000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/myc.70001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/myc.70001"],"URL":"https:\/\/doi.org\/10.1111\/myc.70001","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"2024-09-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70001"}}